The role of lymph node dissection in salvage radical prostatectomy for patients with radiation recurrent prostate cancer.

BCR localized lymphadenectomy metastasis

Journal

The Prostate
ISSN: 1097-0045
Titre abrégé: Prostate
Pays: United States
ID NLM: 8101368

Informations de publication

Date de publication:
08 2021
Historique:
revised: 07 05 2021
received: 13 04 2021
accepted: 14 05 2021
pubmed: 1 6 2021
medline: 1 6 2021
entrez: 31 5 2021
Statut: ppublish

Résumé

To examine the effect of lymph node dissection on the outcomes of patients who underwent salvage radical prostatectomy (SRP). We retrospectively reviewed data from radiation-recurrent patients with prostate cancer (PCa) who underwent SRP from 2000-2016. None of the patients had clinical lymph node involvement before SRP. The effect of the number of removed lymph nodes (RLNs) and the number of positive lymph nodes (PLNs) on biochemical recurrence (BCR)-free survival, metastases free survival, and overall survival (OS) was tested in multivariable Cox regression analyses. About 334 patients underwent SRP and pelvic lymph node dissection (PLND). Lymph node involvement was associated with increased risk of BCR (p < .001), metastasis (p < .001), and overall mortality (p = .006). In a multivariable Cox regression analysis, an increased number of RLNs significantly lowered the risk of BCR (hazard ratio [HR] 0.96, p = .01). In patients with positive lymph nodes, a higher number of RLNs and a lower number of PLNs were associated with improved freedom from BCR (HR 0.89, p = .001 and HR 1.34, p = .008, respectively). At a median follow-up of 23.9 months (interquartile range, 4.7-37.7), neither the number of RLNs nor the number of PLNs were associated with OS (p = .69 and p = .34, respectively). Pathologic lymph node involvement increased the risk of BCR, metastasis and overall mortality in radiation-recurrent PCa patients undergoing SRP. The risk of BCR decreased steadily with a higher number of RLNs during SRP. Further research is needed to support this conclusion and develop a precise therapeutic adjuvant strategy based on the number of RLNs and PLNs.

Identifiants

pubmed: 34057227
doi: 10.1002/pros.24173
pmc: PMC8361975
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

765-771

Informations de copyright

© 2021 The Authors. The Prostate published by Wiley Periodicals LLC.

Références

Eur J Nucl Med Mol Imaging. 2019 Sep;46(10):2169-2177
pubmed: 31254037
Urology. 2002 Sep;60(3 Suppl 1):57-62; discussion 62-3
pubmed: 12231051
Eur Urol. 2015 Feb;67(2):212-9
pubmed: 24882672
Int J Radiat Oncol Biol Phys. 2003 Nov 15;57(4):915-28
pubmed: 14575822
BJU Int. 2020 Dec;126(6):679-683
pubmed: 32531840
BJU Int. 2007 Dec;100(6):1254-8
pubmed: 17979925
Urol Oncol. 2019 Feb;37(2):123-129
pubmed: 30522902
J Urol. 2007 Sep;178(3 Pt 1):864-70; discussion 870-1
pubmed: 17631342
Cancer. 2008 Jan 15;112(2):307-14
pubmed: 18050294
Eur Urol Oncol. 2020 Oct;3(5):565-581
pubmed: 32933887
J Clin Med. 2019 Mar 11;8(3):
pubmed: 30862069
BJU Int. 2011 Sep;108(5):724-8
pubmed: 21166755
CA Cancer J Clin. 2020 Nov;70(6):443-459
pubmed: 32940362
Eur Urol. 2012 May;61(5):961-71
pubmed: 22280856
Clin Genitourin Cancer. 2016 Jun;14(3):218-25
pubmed: 26774347
Clin Cancer Res. 2018 Dec 15;24(24):6300-6307
pubmed: 30139879
Prostate. 2014 Feb;74(2):210-6
pubmed: 24132735
Prostate. 2021 Aug;81(11):765-771
pubmed: 34057227
Eur J Nucl Med Mol Imaging. 2016 Mar;43(3):397-403
pubmed: 26563121
J Urol. 1998 Mar;159(3):950-4; discussion 954-5
pubmed: 9474190
Clin Genitourin Cancer. 2018 Jun;16(3):e619-e627
pubmed: 29239845
Eur Urol. 2010 Mar;57(3):437-43
pubmed: 19303197
Eur Urol. 2019 Jun;75(6):967-987
pubmed: 30342843
J Urol. 2020 Aug;204(2):296-302
pubmed: 32068488
Prostate. 2021 May;81(6):339-346
pubmed: 33666271
Int J Radiat Oncol Biol Phys. 2006 Jul 15;65(4):965-74
pubmed: 16798415
Future Oncol. 2009 Dec;5(10):1555-84
pubmed: 20001796
Eur Urol. 2010 Nov;58(5):687-700
pubmed: 20727668
Minerva Urol Nefrol. 2020 Sep 29;:
pubmed: 32993278
Arab J Urol. 2020 May 31;18(4):213-218
pubmed: 33312731
Eur Urol. 2011 Aug;60(2):205-10
pubmed: 21420229
Cancer. 1993 Feb 1;71(3 Suppl):976-80
pubmed: 8428347
BJU Int. 2006 Aug;98(2):329-34
pubmed: 16879673
Urology. 2007 Jan;69(1):147-51
pubmed: 17270638
J Clin Oncol. 1997 Jan;15(1):230-8
pubmed: 8996147
Eur Urol. 2014 Mar;65(3):554-62
pubmed: 24094576

Auteurs

Fahad Quhal (F)

Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
Department of Urology, King Fahad Specialist Hospital, Dammam, Saudi Arabia.

Pawel Rajwa (P)

Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
Department of Urology, Medical University of Silesia, Zabrze, Poland.

Keiichiro Mori (K)

Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
Department of Urology, The Jikei University School of Medicine, Tokyo, Japan.

Ekaterina Laukhtina (E)

Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia.

Nico C Grossmann (NC)

Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
Department of Urology, University Hospital Zurich, Zurich, Switzerland.

Victor M Schuettfort (VM)

Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Frederik König (F)

Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Abdulmajeed Aydh (A)

Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
Department of Urology, King Faisal Medical City, Abha, Saudi Arabia.

Reza S Motlagh (RS)

Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
Men's Health and Reproductive Health Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Satoshi Katayama (S)

Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
Department of Urology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan.

Hadi Mostafai (H)

Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
Research Center for Evidence Based Medicine, Tabriz University of Medical Sciences, Tabriz, Iran.

Benjamin Pradere (B)

Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.

Giancarlo Marra (G)

Division of Urology, Department of Surgical Sciences, San Giovanni Battista Hospital, University of Studies of Torino, Turin, Italy.

Paolo Gontero (P)

Division of Urology, Department of Surgical Sciences, San Giovanni Battista Hospital, University of Studies of Torino, Turin, Italy.

Romain Mathieu (R)

Department of Urology, Rennes University Hospital, Rennes, France.

Pierre I Karakiewicz (PI)

Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Centre, Montreal, Canada.

Alberto Briganti (A)

Department of Urology, Vita Salute San Raffaele University, Milan, Italy.

Shahrokh F Shariat (SF)

Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia.
Department of Urology, Weill Cornell Medical College, New York City, New York, USA.
Department of Urology, University of Texas Southwestern, Dallas, Texas, USA.
Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic.
Division of Urology, Department of Special Surgery, Jordan University Hospital, The University of Jordan, Amman, Jordan.

Axel Heidenreich (A)

Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
Department of Urology, University Hospital Cologne, Cologne, Germany.

Classifications MeSH